A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study.


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
08 2021
Historique:
received: 10 05 2021
revised: 08 07 2021
accepted: 12 07 2021
pubmed: 23 7 2021
medline: 18 9 2021
entrez: 22 7 2021
Statut: ppublish

Résumé

In 2020 the coronavirus disease 19 (COVID-19) pandemic imposed a total and sudden lockdown. We aimed to investigate the consequences of the first COVID-19 lockdown (mid-March - mid-April 2020) on motor and non-motor symptoms (NMS) in a cohort of French people with Parkinson's disease (PwP). PwP were enrolled either by an on-line survey sent from the national France Parkinson association (FP) to reach the French community of PwP or as part of outpatients' telemedicine visits followed by an hospital-based Parkinson Expert Center (PEC). All patients were evaluated using the same standardized questionnaire assessing motor and NMS (including a list of most disabling, new or worsened symptoms and Patient's Global Impression-Improvement scales [PGI-I]) psycho-social queries and quality of life. 2653 PwP were included: 441 (16.6%) in the PEC group and 2122 (83.4%) in the community-based group. Physiotherapy was interrupted among 88.6% of the patients. 40.9% referred a clinical modification of their symptoms. Based on the questionnaire, pain (9.3%), rigidity (9.1%) and tremor (8.5%) were the three most frequently new or worsened reported symptoms. Based on the PGI-I, the motor symptoms were the most affected domain, followed by pain and psychic state. PwP in community-based group tended to have more frequent worsening for motor symptoms, motor complications, pain and confusion than those of the PEC group. The first COVID-19 lockdown had a negative impact on motor and NMS of PwP. Efforts should be allocated to avoid interruption of care, including physiotherapy and physical activities and implement telemedicine. .

Sections du résumé

BACKGROUND
In 2020 the coronavirus disease 19 (COVID-19) pandemic imposed a total and sudden lockdown. We aimed to investigate the consequences of the first COVID-19 lockdown (mid-March - mid-April 2020) on motor and non-motor symptoms (NMS) in a cohort of French people with Parkinson's disease (PwP).
METHODS
PwP were enrolled either by an on-line survey sent from the national France Parkinson association (FP) to reach the French community of PwP or as part of outpatients' telemedicine visits followed by an hospital-based Parkinson Expert Center (PEC). All patients were evaluated using the same standardized questionnaire assessing motor and NMS (including a list of most disabling, new or worsened symptoms and Patient's Global Impression-Improvement scales [PGI-I]) psycho-social queries and quality of life.
RESULTS
2653 PwP were included: 441 (16.6%) in the PEC group and 2122 (83.4%) in the community-based group. Physiotherapy was interrupted among 88.6% of the patients. 40.9% referred a clinical modification of their symptoms. Based on the questionnaire, pain (9.3%), rigidity (9.1%) and tremor (8.5%) were the three most frequently new or worsened reported symptoms. Based on the PGI-I, the motor symptoms were the most affected domain, followed by pain and psychic state. PwP in community-based group tended to have more frequent worsening for motor symptoms, motor complications, pain and confusion than those of the PEC group.
CONCLUSIONS
The first COVID-19 lockdown had a negative impact on motor and NMS of PwP. Efforts should be allocated to avoid interruption of care, including physiotherapy and physical activities and implement telemedicine. .

Identifiants

pubmed: 34293534
pii: S1353-8020(21)00262-5
doi: 10.1016/j.parkreldis.2021.07.013
pmc: PMC9272278
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

128-133

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Références

Mov Disord. 2020 Jun;35(6):912-914
pubmed: 32304118
J Clin Med. 2020 Nov 05;9(11):
pubmed: 33167322
J Neurol. 2021 Apr;268(4):1222-1246
pubmed: 31414194
Eur J Neurol. 2021 Oct;28(10):3254-3262
pubmed: 33460507
Mov Disord. 2020 Dec;35(12):2129-2133
pubmed: 32860226
J Parkinsons Dis. 2020;10(2):351-354
pubmed: 32250324
Mov Disord. 2020 Oct;35(10):1701-1711
pubmed: 32833273
Mov Disord Clin Pract. 2020 May 04;7(4):361-372
pubmed: 32373652
J Parkinsons Dis. 2021;11(3):1047-1056
pubmed: 33780375
Mov Disord. 2010 Aug 15;25(11):1646-51
pubmed: 20629164
J Parkinsons Dis. 2020;10(4):1355-1364
pubmed: 32925108
J Clin Med. 2020 May 29;9(6):
pubmed: 32486074
Mov Disord Clin Pract. 2020 Aug 17;7(7):797-802
pubmed: 32837960
Parkinsonism Relat Disord. 2020 Nov;80:7-9
pubmed: 32920322
Mov Disord. 2020 May;35(5):711-715
pubmed: 32250460
Mov Disord. 2020 Jul;35(7):1095-1096
pubmed: 32395849

Auteurs

Margherita Fabbri (M)

Service de Neurologie, Centre Hospitalier Universitaire, Toulouse, France; France CHU de Toulouse, Université de Toulouse-Toulouse 3, INSERM, UMR1214 Toulouse NeuroImaging Centre "TONIC," Center of Excellence in Neurodegeneration (CoEN), NeuroToul, Centre Expert Parkinson de Toulouse, Centre d'Investigation Clinique CIC1436, NS-Park/FCRIN Network, Services de Neurologie et de Pharmacologie Clinique, UMR 1048 Institute for Cardiovascular Diseases, Toulouse, France. Electronic address: margheritafabbrimd@gmail.com.

Clémence Leung (C)

Service de Neurologie, Centre Hospitalier Universitaire, Toulouse, France.

Guillaume Baille (G)

Service de Neurologie, Hôpital Delafontaine, Saint-Denis, France.

Matthieu Béreau (M)

Service de Neurologie, Centre Hospitalier Universitaire, Besançon, France.

Christine Brefel Courbon (C)

Service de Neurologie, Centre Hospitalier Universitaire, Toulouse, France; France CHU de Toulouse, Université de Toulouse-Toulouse 3, INSERM, UMR1214 Toulouse NeuroImaging Centre "TONIC," Center of Excellence in Neurodegeneration (CoEN), NeuroToul, Centre Expert Parkinson de Toulouse, Centre d'Investigation Clinique CIC1436, NS-Park/FCRIN Network, Services de Neurologie et de Pharmacologie Clinique, UMR 1048 Institute for Cardiovascular Diseases, Toulouse, France; Service de Pharmacologie Médicale et Clinique - CHU Toulouse Université de Toulouse, France.

Giovanni Castelnovo (G)

Service de Neurologie, Centre Hospitalier Universitaire, NS-Park/FCRIN Network, Nîmes, France.

Nicolas Carriere (N)

Service de Neurologie, Centre Hospitalier Universitaire, NS-Park/FCRIN Network, Lille, France.

Philippe Damier (P)

Service de Neurologie, Centre Hospitalier Universitaire, NS-Park/FCRIN Network, Nantes, France.

Luc Defebvre (L)

Service de Neurologie, Centre Hospitalier Universitaire, NS-Park/FCRIN Network, Lille, France.

Anne Doe de Maindreville (A)

Service de Neurologie, Centre Hospitalier Universitaire, NS-Park/FCRIN Network, Reims, France.

Frederique Fluchere (F)

Service de Neurologie, Centre Hospitalier Universitaire la Timone, Aix-Marseille University, NS-Park/FCRIN Network, France.

Marie Fuzzatti (M)

Association France Parkinson, France.

David Grabli (D)

Service de Neurologie, Centre Hospitalier Universitaire, NS-Park/FCRIN Network, Pitié-Salpêtrière, France.

David Maltete (D)

Service de Neurologie, Centre Hospitalier Universitaire, Rouen, France; INSERM U1239, Laboratoire de Différenciation et Communication Neuronale et Neuroendocrinienne, NS-Park/FCRIN Network, Mont-Saint-Aignan, France.

Vanessa Rousseau (V)

Service de Pharmacologie Médicale et Clinique - CHU Toulouse Université de Toulouse, France; Unité MeDatAS, Centre d'Investigation Clinique, Centre Hospitalier Universitaire, Toulouse, France.

Agnès Sommet A (A)

Service de Pharmacologie Médicale et Clinique - CHU Toulouse Université de Toulouse, France; Unité MeDatAS, Centre d'Investigation Clinique, Centre Hospitalier Universitaire, Toulouse, France.

Claire Thalamas (C)

France CHU de Toulouse, Université de Toulouse-Toulouse 3, INSERM, UMR1214 Toulouse NeuroImaging Centre "TONIC," Center of Excellence in Neurodegeneration (CoEN), NeuroToul, Centre Expert Parkinson de Toulouse, Centre d'Investigation Clinique CIC1436, NS-Park/FCRIN Network, Services de Neurologie et de Pharmacologie Clinique, UMR 1048 Institute for Cardiovascular Diseases, Toulouse, France.

Claire Thiriez (C)

Service de Neurologie, Centre Hospitalier Universitaire, NS-Park/FCRIN Network, Caen, France.

Olivier Rascol (O)

Service de Neurologie, Centre Hospitalier Universitaire, Toulouse, France; France CHU de Toulouse, Université de Toulouse-Toulouse 3, INSERM, UMR1214 Toulouse NeuroImaging Centre "TONIC," Center of Excellence in Neurodegeneration (CoEN), NeuroToul, Centre Expert Parkinson de Toulouse, Centre d'Investigation Clinique CIC1436, NS-Park/FCRIN Network, Services de Neurologie et de Pharmacologie Clinique, UMR 1048 Institute for Cardiovascular Diseases, Toulouse, France; Service de Pharmacologie Médicale et Clinique - CHU Toulouse Université de Toulouse, France.

Fabienne Ory-Magne (F)

Service de Neurologie, Centre Hospitalier Universitaire, Toulouse, France; France CHU de Toulouse, Université de Toulouse-Toulouse 3, INSERM, UMR1214 Toulouse NeuroImaging Centre "TONIC," Center of Excellence in Neurodegeneration (CoEN), NeuroToul, Centre Expert Parkinson de Toulouse, Centre d'Investigation Clinique CIC1436, NS-Park/FCRIN Network, Services de Neurologie et de Pharmacologie Clinique, UMR 1048 Institute for Cardiovascular Diseases, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH